Natalizumab Therapy for Highly Active Pediatric Multiple Sclerosis

JAMA Neurology - United States
doi 10.1001/jamaneurol.2013.923
Full Text
Abstract

Available in full text

Categories
Neurology
Date
Authors
Publisher

American Medical Association (AMA)

Related search

Alemtuzumab Following Natalizumab in Highly Active Paediatric-Onset Multiple Sclerosis

Multiple Sclerosis Journal - Experimental, Translational and Clinical
2019English

Cladribine for Highly Active Relapsing Multiple Sclerosis

Prescriber
Pharmacology
2018English

Natalizumab Treatment in Multiple Sclerosis

Clinical Neurology
Neurology
2015English

Cyclophosphamide Therapy in Pediatric Multiple Sclerosis

Neurology
Neurology
2009English

Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis

Advances in Therapy
MedicinePharmacology
2019English

Natalizumab: A New Treatment for Relapsing Remitting Multiple Sclerosis

Therapeutics and Clinical Risk Management
Chemical HealthPharmacologySafetyMedicineToxicologySafety ResearchPharmaceutics
2007English

Pediatric Multiple Sclerosis

Neurology
Neurology
2016English

Pediatric Multiple Sclerosis

2016English

Predictors for Multiple Sclerosis Relapses After Switching From Natalizumab to Fingolimod

Multiple Sclerosis
Neurology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy